NASDAQ: TECH
Bio Techne Corp Stock

$54.02+1.52 (+2.9%)
Updated Jun 11, 2026
TECH Price
$54.02
Fair Value Price
$25.41
Market Cap
$8.46B
52 Week Low
$43.20
52 Week High
$72.16
P/E
76.08x
P/B
4.06x
P/S
6.75x
PEG
1.57x
Dividend Yield
0.59%
Revenue
$1.21B
Earnings
$109.56M
Gross Margin
65%
Operating Margin
12.86%
Profit Margin
9%
Debt to Equity
0.22
Operating Cash Flow
$295M
Beta
1.15
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A

TECH Overview

Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TECH's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TECH
Ranked
#46 of 463

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$236.17A
$53.50A
$15.85A
View Top Biotech Stocks

Be the first to know about important TECH news, forecast changes, insider trades & much more!

TECH News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TECH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TECH ($54.02) is overvalued by 112.61% relative to our estimate of its Fair Value price of $25.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TECH ($54.02) is not significantly undervalued (112.61%) relative to our estimate of its Fair Value price of $25.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TECH ($54.02) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more TECH due diligence checks available for Premium users.

Valuation

TECH fair value

Fair Value of TECH stock based on Discounted Cash Flow (DCF)

Price
$54.02
Fair Value
$25.41
Overvalued by
112.61%
TECH ($54.02) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TECH ($54.02) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TECH ($54.02) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TECH price to earnings (PE)

For valuing profitable companies with steady earnings

Company
76.08x
Industry
17.66x
Market
13.95x
TECH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TECH is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

TECH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.06x
Industry
4.83x
TECH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TECH price to earnings growth (PEG)

For valuing profitable companies with growth potential

TECH is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

TECH's financial health

Profit margin

Revenue
$311.4M
Net Income
$51.0M
Profit Margin
16.4%
TECH's Earnings (EBIT) of $155.65M... subscribe to Premium to read more.
Interest Coverage Financials
TECH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.6B
Liabilities
$465.3M
Debt to equity
0.22
TECH's short-term assets ($688.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TECH's short-term assets ($688.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TECH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TECH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$86.7M
Investing
-$5.8M
Financing
-$42.7M
TECH's operating cash flow ($294.86M)... subscribe to Premium to read more.
Debt Coverage Financials

TECH vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TECHC$8.46B+2.90%76.08x4.06x
HALOB$8.39B+0.33%23.90x38.20x
CYTKC$8.62B+3.28%-10.13x-10.43x
CORTC$8.94B+6.57%180.98x14.01x
ABVXC$7.96B+2.90%-19.10x15.76x

Bio Techne Stock FAQ

What is Bio Techne's quote symbol?

(NASDAQ: TECH) Bio Techne trades on the NASDAQ under the ticker symbol TECH. Bio Techne stock quotes can also be displayed as NASDAQ: TECH.

If you're new to stock investing, here's how to buy Bio Techne stock.

What is the 52 week high and low for Bio Techne (NASDAQ: TECH)?

(NASDAQ: TECH) Bio Techne's 52-week high was $72.16, and its 52-week low was $43.20. It is currently -25.14% from its 52-week high and 25.05% from its 52-week low.

How much is Bio Techne stock worth today?

(NASDAQ: TECH) Bio Techne currently has 156,568,751 outstanding shares. With Bio Techne stock trading at $54.02 per share, the total value of Bio Techne stock (market capitalization) is $8.46B.

Bio Techne stock was originally listed at a price of $2.22 in Dec 31, 1997. If you had invested in Bio Techne stock at $2.22, your return over the last 28 years would have been 2,334.43%, for an annualized return of 12.08% (not including any dividends or dividend reinvestments).

How much is Bio Techne's stock price per share?

(NASDAQ: TECH) Bio Techne stock price per share is $54.02 today (as of Jun 11, 2026).

What is Bio Techne's Market Cap?

(NASDAQ: TECH) Bio Techne's market cap is $8.46B, as of Jun 13, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Bio Techne's market cap is calculated by multiplying TECH's current stock price of $54.02 by TECH's total outstanding shares of 156,568,751.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.